rage its comprehensive patient-focused commercialization platform—encompassing disease awareness, diagnosis support, market access, and patient affordability programs—to ensure this therapy reaches the families affected by this devastating rare epilepsy.

"Bringing the first approved therapy for CDKL5 deficiency disorder to patients in China represents exactly the type of mission-critical work Golden Age Health was built for," saidChao (Brook) Wu, Chief Executive Officer of Golden Age Health (Shanghai). "We are honored to partner with Tenacia to ensure that children and families affected by CDD can access this breakthrough treatment as quickly as possible."

Dr. Xiaoxiang Chen, Founder and CEO of Tenacia Biopharmaceuticals (Shanghai), said: "GAH's proven expertise in rare disease commercialization and their commitment to patient access make them the ideal partner to bring ZTALMY®to the patients who need it most in China. Together, we w
=*=*=*=*=*=
当前为第2/5页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页